Theracryf Plc (TCF.L)

0,7500 0,0000 (0,00%) Alla chiusura: 09:39AM BST

Theracryf Plc

Alderley Park
Suite 24G13 - Block 24 Congleton Road
Nether Alderley SK10 4TG
United Kingdom
44 1625 315 090
https://theracryf.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 10

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Huw Jones BSc, Ph.D.	CEO & Executive Director	304,73k	N/D	1959
Mr. Toni Haenninen	CFO & Director	N/D	N/D	1977
Dr. Helen Kuhlman Ph.D.	Chief Business Officer	N/D	N/D	N/D
Dr. Glen Clack FFPM, M.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy. The company has a partnership with Stalicla to collaborate on a clinical program in autism spectrum disorder. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Theracryf Plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.